The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer

Thyroid

Volumn 24, Issue 4, 2014, Pages 758-763

  Zevallos, Jose P ^a   Xu, Li ^b   Yiu, Yin ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ABLATION THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SIZE; CONTROLLED STUDY; DATA BASE; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HEALTH CARE DISPARITY; HEALTH INSURANCE; HOUSEHOLD; HUMAN; INCOME; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SOCIAL STATUS; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; ADJUVANT THERAPY; CANCER REGISTRY; CARCINOMA, PAPILLARY; COHORT ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; SOCIAL CLASS; THYROID NEOPLASMS; UNITED STATES; UTILIZATION;

ADULT; CARCINOMA, PAPILLARY; COHORT STUDIES; FEMALE; HEALTHCARE DISPARITIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SEER PROGRAM; SOCIAL CLASS; THYROID NEOPLASMS; THYROIDECTOMY; UNITED STATES;

EID: 84898422787     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0409     Document Type: Article

References (30)

1. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, Thun M 2004 Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78-93
2. Yin D, Morris C, Allen M, Cress R, Bates J, Liu L 2010 Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control 21:1721-1730
3. Wudel LJ Jr, Chapman WC, Shyr Y, Davidson M, Jeyakumar A, Rogers SO Jr, Allos T, Stain SC 2002 Disparate outcomes in patients with colorectal cancer: Effect of race on long-term survival. Arch Surg 137:550-554; discussion 554-556
4. Morris LG, Sikora AG, Tosteson TD, Davies L 2013 The increasing incidence of thyroid cancer: The influence of access to care. Thyroid 23:885-891
5. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM 2013 Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: Review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 23: 103-110
6. Lim II, Hochman T, Blumberg SN, Patel KN, Heller KS, Ogilvie JB 2012 Disparities in the initial presentation of differentiated thyroid cancer in a large public hospital and adjoining university teaching hospital. Thyroid 22:269-274
7. Siu S, McDonald JT, Rajaraman M, Franklin J, Paul T, Rachinsky I, Morrison D, Imran SA, Burrell S, Hart R, Driedger A, Badreddine M, Yoo J, Corsten M, Van Uum S 2014 Is lower socioeconomic status associated with more advanced thyroid cancer stage at presentation? A study in two Canadian centers. Thyroid 24:545-551
8. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in welldifferentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457-480, x.
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
10. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ 2011 Use of radioactive iodine for thyroid cancer. JAMA 306:721-728
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds) 2010 AJCC Cancer Staging Manual, 7th ed. Springer, New York
12. Krieger N, Chen JT, Waterman PD 2010 Decline in US breast cancer rates after the Women's Health Initiative: Socioeconomic and racial/ethnic differentials. Am J Public Health 100 Suppl 1:S132-S139
13. Yost K, Perkins C, Cohen R, Morris C, Wright W 2001 Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703-711
14. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman ME 2008 An overview of methods for monitoring social disparities in cancer with an example using trends in lung cancer incidence by area-socioeconomic position and race-ethnicity, 1992-2004. Am J Epidemiol 167:889-899
15. Trevino KM, Fasciano K, Prigerson HG 2013 Patientoncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer. J Clin Oncol 31:1683-1689
16. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ 2013 Patient characteristics associated with medication adherence. Clin Med Res 11:54-65
17. Cohen RA, Bloom B 2010 Access to and utilization of medical care for young adults ages 20-29 years: United States, 2008. NCHS Data Brief 2010:1-8
18. Driscoll AK, Bernstein AB 2012 Health and access to care among employed and unemployed adults: United States, 2009-2010. NCHS Data Brief 2012:1-8
19. Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart MR 2013 Factors that influence radioactive iodine use for thyroid cancer. Thyroid 23:219-224
20. Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M 2013 Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab 98:678-686
21. Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ2013The roleofclinicians indeterminingradioactive iodine use for low-risk thyroid cancer. Cancer 119:259-265
22. Lin JH, Zhang SM, Manson JE 2011 Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila) 4:1360-1365
23. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP 2013 The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 23:683-694
24. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffé S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau M 2012 Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 97:1526-1535
25. Lee SL 2010 Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 8:1277- quiz 1287
26. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and metaanalysis. Thyroid 19:451-457
27. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with lowrisk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 117:4439-4446
28. KriegerN, ChenJT, WatermanPD, RehkopfDH, Subramanian SV 2005 Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: The Public Health Disparities Geocoding Project. AmJ Public Health 95:312-323
29. Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R 2002 Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: Does the choice of area-based measure and geographic level matter? The Public Health Disparities Geocoding Project. Am J Epidemiol 156:471-482
30. Krieger N, Williams DR, Moss NE 1997 Measuring social class in US public health research: Concepts, methodologies, and guidelines. Annu Rev Public Health 18:341-378.